GN-037 is under clinical development by Gen Ilac ve Saglik Urunleri and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GN-037’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GN-037 is under development for the treatment of mild to moderate plaque psoriasis. The therapeutic candidate is administered through topical route in the form of cream.
Gen Ilac ve Saglik Urunleri overview
Gen Ilac ve Saglik Urunleri (Gen Ilac ve) is a specialty pharmaceutical company to bring innovative therapies and rare solutions to our community. The company is headquartered in Ankara, Turkey.
For a complete picture of GN-037’s drug-specific PTSR and LoA scores, buy the report here.